Akero Therapeutics (NASDAQ: AKRO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $22.00 price target on the stock.
Akero Therapeutics, Inc. (AKRO)
Last akero therapeutics, inc. earnings: 3/16 07:30 am
Check Earnings Report
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
AKRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRO alerts
High impacting Akero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKRO
News
- Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is InvestiGlobeNewswire
- Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "overweight" rating re-affirmed by analysts at Morgan Stanley.MarketBeat
- Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at HC Wainwright from $72.00 to $75.00. They now have a "buy" rating on the stock.MarketBeat
- Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswire
AKRO
Earnings
- 11/8/24 - Miss
AKRO
Sec Filings
- 3/18/25 - Form 4
- 3/14/25 - Form 4
- 3/14/25 - Form 4
- AKRO's page on the SEC website